Context Therapeutics® and Tyligand Bioscience Reach ONA-XR Manufacturing Optimization Milestone

advance medicines for female cancers
Published on : Published by : BioBuzz Media

Context Therapeutics Inc., a women’s oncology company developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers, and Tyligand Bioscience, Ltd., a leader in small molecule drug discovery and development, today announced the successful completion of ONA-XR (onapristone extended release) manufacturing process optimization pursuant to the collaboration agreement entered into between the parties in March 2020.

WindMIL Therapeutics Appoints Dr. Kimberly Noonan as Chief Science & Technology Officer

Published on : Published by : BioBuzz Media

WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs®) for cancer immunotherapy, today announced the appointment of Co-Founder Kimberly Noonan, PhD, MPH, to Executive Vice President, Chief Science & Technology Officer. In this role, Dr. Noonan’s leadership will expand to include WindMIL’s efforts in manufacturing and manufacturing science and technology (MS&T).

Patent for Patients: A Boon for Cancer Immunotherapy

Published on : Published by : Nivedita Uday Hegdekar

Over the recent decades, cancer immunotherapy research has made significant advances. In our continued quest to cure cancer, a commercial incentive is necessary to counterbalance the costs and risks associated with the research and development of cancer immunotherapies and to encourage new inventions.

Rockville’s MacroGenics Enters Research Collaboration with Sweden’s Alligator Bioscience to Develop a Novel Immunotherapy

Published on : Published by : BioBuzz Media

Under the joint research collaboration agreement, which covers activities from candidate drug generation up until IND-enabling studies, each company will be responsible for its own costs. The parties may continue further development of the resulting bispecific molecule under a separate co-development collaboration and licensing agreement.

Germantown’s Precigen Announces First Patient Dosed for PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis (RRP)

Published on : Published by : BioBuzz Media

Germantown’s Precigen Announces First Patient Dosed for PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis (RRP) GERMANTOWN, Md., March 23, 2021 /PRNewswire/ — Precigen, Inc., a biopharmaceutical company specializing in the development [….]

Rockville’s Sensei Biotherapeutics Announces $30 Million Financing to Advance Clinical Pipeline of Oncology Therapeutics and Proprietary ImmunoPhage™ Platform

Published on : Published by : BioBuzz Media

– Round co-led by Apeiron Investment Group and Catalio Capital Management – Proceeds support advancement of lead product candidate and next-generation platform for personalized yet off-the-shelf cancer immunotherapies BOSTON & [….]

Weekly Roundup of COVID-19 Progress From T-Cell to Microbiome Therapies and FDA Emergency Use Applications

Published on : Published by : Steven Surdez

Weekly Roundup of COVID-19 Progress From T-Cell to Microbiome Therapies and FDA Emergency Use Applications April 21, 2020 Organizations from across the BioHealth Capital Region (BCHR) continue to pivot research, [….]

Leidos’s New Virtual Biotech Startup ‘ExGloH’ Targets Cancer and Infectious Diseases with Improved T Cell Therapies

Published on : Published by : Steven Surdez

Leidos’s New Virtual Biotech Startup ‘ExGloH’ Targets Cancer and Infectious Diseases with Improved T Cell Therapies Leidos’s ExGloH Leverages Entrepreneurial Science and Industry-Leading Support Infrastructure to Improve Global Health June [….]